The Pharma Data
DECEMBER 23, 2020
All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g., ClinicalTrials.gov identifier: NCT04336410.
Drug Discovery World
APRIL 14, 2023
The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 29, 2022
W911QY-21-9-0001. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Bioengineer
JULY 15, 2021
But some patients develop resistance to current immunotherapies and others have cancers characterized by immunologically “cold” tumors, which evade or suppress the patient’s immune response against his or her cancer. Additional authors on this research are Peter Carlson, Joseph Grudinski, Ph.D., ” ###.
The Pharma Data
MARCH 25, 2022
The half-life extension more than triples the durability of its action compared to conventional antibodies;(11-13) data from the PROVENT Phase III trial show protection lasting at least six months.(14) W911QY-21-9-0001.
The Pharma Data
MAY 16, 2021
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.
The Pharma Data
AUGUST 22, 2021
More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. W911QY-21-9-0001.
Expert insights. Personalized for you.
40 
Let's personalize your content